2024 SV Therapeutics Impact & ESG ReportRead More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 8 September 2022Portfolio NewsArtemis Health and Zerigo Health Announce Partnership to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditions
- 17 August 2022Portfolio NewsPodimetrics Declares War on Diabetic Foot Amputations
- 9 August 2022Portfolio NewsNanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Health
- 13 July 2022Portfolio NewsFDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer
- 25 March 2022Portfolio NewsPodimetrics Secures $45M for SmartMat to Prevent Diabetic Amputations in High-Risk Patients
- 2 March 2022Portfolio NewsAlpheus Medical Announces Formation of World-Class Scientific Advisory Board (SAB) to Support Development of Novel Treatment for Brain Cancer
- 9 February 2022SV NewsNeurovascular company Perfuze raises €22.5M ($25M) Series A for a new stroke treament
- 5 January 2022Portfolio NewsEndotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study
- 4 January 2022Portfolio NewsCarePredict, Inc. is mentioned in The Wall Street Journal as a top trend to watch in CES2022
- 14 December 2021Portfolio NewsZerigo Health Expands Board of Directors
- 17 November 2021Portfolio NewsAlpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
- 4 November 2021SV NewsVibrato Medical announced that Paul A. LaViolette has been appointed to its board of directors.